Introduction
The classical treatment for the control of signs due to congestive heart failure (CHF) includes diuretics, vasodilators and antiarrhythmic drugs. Pimobendan (Vetmedin®) is a novel drug with phosphodiesterase-inhibiting and calcium-sensitising effects that increase myocardial contractility, promote arterial and venous dilatation and could be effective for the treatment of congestive heart failure (CHF) in dogs. (Smith et al., 2005; Gordon et al., 2006; Lombard et al., 2006; Kanno et al., 2007; Häggström et al., 2008) . The aim of the study was to evaluate the short-term effects of pimobendan on clinical, laboratory, radiological, electrocardiographic and echocardiographic observations in dogs with naturally occurring mitral valve myxomatous disease.
Materials and Methods
The present study was a prospective, descriptive, observational study (before and after trial). We considered just one working group: Dogs suffering from Congestive Heart Failure (CHF) due to myxomatous valve disease (MVD). The criteria included were: dogs present with a moderate to high intensity heart murmur with maximal intensity over the mitral area, with echocardiographic evidence of mixomatous mitral valve disease, evidence of moderate to severe left atrial or left ventricular enlargement on B-dimensional study and mitral regurgitation in colour Doppler study. The dogs did not show any evidence of other significant systemic disease or CHF due to congenital heart disease.
The study involved twenty patients with CHF secondary to MVD in phases 2 or 3 according to the Scandinavian modified New York Heart Association system (Kvart et al., 2002) , with no previous treatment. Patients were attended in the Cardiology Service of the Faculty of Veterinary Medicine at the Complutense University, Madrid. Clinical history, complete physical examination including body weight and electrocardiographic study were made. Radiological study, including right lateral and dorso-ventral thoracic radiograph, to determine the degree of cardiomegaly according to the cardio-vertebral index and the degree of congestion-oedema in the lung was made. Finally, an echocardiographic study and a routine Slight symptoms: Dog is coughing from time to time during the night, but no other clinical signs of dyspnoea or uneasiness are present. Obvious symptoms: Dog shows symptoms of coughing, increased respiratory effort or uneasiness during the night.
c Score 1: Asymptomatic dog with murmurs but no cardiac enlargement. Score 2: Asymptomatic dog with murmurs cardiac enlargement but no pulmonary oedema or congestion. Score 3: moderately symptomatic dog (dyspnoea, increased heart rate and disappearance of sinus arrhythmia) with murmurs, cardiac enlargement and interstitial pulmonary oedema. Score 4: Severely symptomatic dog with murmurs, cardiac enlargement and pulmonary oedema. haematology and clinical chemistry were also performed. The data was collected on unseated patients using the usual cardiologic standards on an outpatient basis. The echocardiographic examination was performed to compare the effects of the drug on heart chamber size and wall motion. The echocardiographic measurements included fractional shortening, left ventricular internal dimensions in systole and diastole, internal dimension of left atrium and dimension of aorta.
All the animals included in the study were fed during the study period with a commercial or home hyposodic diet. All the patients were reviewed weekly and a record was kept of possible secondary effects or intolerance to treatment, especially cough and/or cardiac arrhythmias. Four weeks after the beginning of treatment, the initial tests were repeated in order to compare the final state of patients with the initial data. The symptoms described in the anamnesis of this first visit were classified according to severity and are shown in Tables 2 a, b.
Medical treatment involved the administration of pimobendan (Vetmedin®) according to the dosing schedule instructions of the manufacturer (Boehringer Ingelheim Vetmedica GmbH, Germany).
Results and Discussion
In general, most patients improved with regard to clinical symptoms (Table 2 ). Intolerance to exercise showed a clear and significant improvement throughout the study, with the result that all patients had a lower degree of intolerance after treatment.
The radiological study showed that the degree of pulmonary congestion decreased significantly (Fig. 2a,b) . Echocardiographic study showed a significant increase in the fractional shortening value.
At the moment, the therapy of cardiac insufficiency is based on two principles: reduction of the heart work and strengthening of its contractility, pimobendan showed both properties. We observed a good outcome in the patients during the period of study (Table 3) similar to other clinical trials (Gordon et al., 2006; Lombard et al., 2006; Kanno et al., 2007; Häggström et al., 2008; Oullet et al., 2009) 
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There is evidence that pimobendan in addition to standard therapy, will increase survival in dogs with CHF secondary to MVD. (Gordon et al., 2006; Lombard et al., 2006 , Häggström et al., 2008 . There was no mortality in this study either. With respect to security, the patients in this study did not develop arrhythmias and the heart frequency was stable during the study. We did not observe adverse changes in biochemical parameters especially with respect to renal and hepatic function. These results agree with other clinical trials (Gordon et al., 2006; Lombard et al., 2006,) . We did not find any undesirable outcomes in the patient but this might be due to the short period of study. Longer period studies are warranted to prove it. 
